<DOC>
	<DOCNO>NCT02303860</DOCNO>
	<brief_summary>The purpose study evaluate ORM-12741 concentration blood steady state .</brief_summary>
	<brief_title>Pharmacokinetic Study Multiple Doses ORM-12741 ( Nebula PK 2 )</brief_title>
	<detailed_description>The purpose study evaluate pharmacokinetic safety ORM-12741 multiple oral dosing modify release formulation .</detailed_description>
	<criteria>1 . Written informed consent ( IC ) obtain . 2 . Good general health ascertain detailed medical history physical examination . 3 . Females males 18 65 year age ( inclusive ) . 4 . Body mass index ( BMI ) 1830 kg/m2 ( inclusive , BMI = weight/height2 ) . 5 . Weight 50100 kg ( inclusive ) . 6 . Regular intestinal transit ( recent history recurrent constipation , diarrhoea , intestinal problem ) . 1 . Predicted poor compliance inability communicate well investigator study centre personnel . 2 . Veins unsuitable repeated venipuncture cannulation . 3 . Evidence clinically significant cardiovascular , renal , hepatic , haematological , gastrointestinal , pulmonary , metabolicendocrine , neurological , urogenital psychiatric disease judge investigator . 4 . Any condition require regular concomitant treatment ( include vitamin herbal product ) likely need concomitant treatment study . Hormonal contraception hormone replacement therapy allow . 5 . Susceptibility severe allergic reaction . 6 . Intake medication could affect outcome study , within 2 week prior first study treatment administration le 5 time halflife medication . Possible enzyme induce drug discuss casebycase sponsor . 7 . Regular consumption 21 unit alcohol per week male 16 unit per week female ( 1 unit = 4 cl spirit , 13 g alcohol ) . 8 . Current use nicotinecontaining product 5 cigarette equivalent/day . 9 . Inability refrain use nicotinecontaining product stay study centre . 10 . Inability refrain consume caffeinecontaining beverage stay study centre , e.g . propensity develop headache refrain caffeinecontaining beverage . 11 . Blood donation loss significant amount blood within 3 month prior first study treatment administration . 12 . Any clinically significant 12lead electrocardiogram ( ECG ) abnormality 10minute rest supine position screen visit , judge investigator . For example : QTc ( calculate Bazett 's formula ) &gt; 470 msec female 450 msec men . 13 . HR &lt; 45 beats/minute &gt; 100 beats/minute 10minute rest supine position screen visit . 14 . At screen visit systolic blood pressure ( BP ) &lt; 90 mmHg &gt; 150 mmHg 10 minute rest supine position , diastolic BP &lt; 50 mmHg &gt; 90 mmHg 10minute rest supine position , symptomatic orthostatic hypotension , decrease ≥ 20 mmHg systolic BP decrease ≥ 10 mmHg diastolic BP 3 minute stand position . 15 . Any abnormal value laboratory test , vital sign , physical examination finding , opinion investigator could interfere interpretation test result cause health risk subject take part study . 16 . History drug abuse positive result drug abuse test . 17 . Positive serology human immunodeficiency virus antibody ( HIVAgAb ) , hepatitis C virus antibody ( HCVAb ) hepatitis B surface antigen ( HBsAg ) . 18 . Females childbearing potential use proper contraception ( hormonal contraception , intrauterine device [ IUD ] surgical sterilization , spermicidal foam conjunction condom male partner ) study . Use oral/hormonal contraception alone acceptable . ( Note : woman childbearing potential current heterosexual relationship include without contraception accord judgement investigator ) . 19 . Any condition opinion investigator would interfere evaluation result constitute health risk study subject . 20 . Participation clinical drug study within 3 month prior first study treatment administration study earlier participation clinical study ORM12741 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Healthy volunteer study</keyword>
</DOC>